CA2128424A1 - Methode d'identification de precurseurs de cellules t cytolytiques - Google Patents

Methode d'identification de precurseurs de cellules t cytolytiques

Info

Publication number
CA2128424A1
CA2128424A1 CA002128424A CA2128424A CA2128424A1 CA 2128424 A1 CA2128424 A1 CA 2128424A1 CA 002128424 A CA002128424 A CA 002128424A CA 2128424 A CA2128424 A CA 2128424A CA 2128424 A1 CA2128424 A1 CA 2128424A1
Authority
CA
Canada
Prior art keywords
cells
tumor
cytolytic
pbmcs
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002128424A
Other languages
English (en)
Inventor
Pierre G. Coulie
Thierry Boon
Thierry Boon-Falleur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2128424A1 publication Critical patent/CA2128424A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002128424A 1992-01-21 1993-01-07 Methode d'identification de precurseurs de cellules t cytolytiques Abandoned CA2128424A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82393392A 1992-01-21 1992-01-21
US07/823,933 1992-01-21

Publications (1)

Publication Number Publication Date
CA2128424A1 true CA2128424A1 (fr) 1993-07-22

Family

ID=25240169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002128424A Abandoned CA2128424A1 (fr) 1992-01-21 1993-01-07 Methode d'identification de precurseurs de cellules t cytolytiques

Country Status (8)

Country Link
EP (1) EP0624189A4 (fr)
JP (1) JPH07503134A (fr)
KR (1) KR950700402A (fr)
AU (1) AU3435293A (fr)
CA (1) CA2128424A1 (fr)
FI (1) FI943422A0 (fr)
NO (1) NO942660L (fr)
WO (1) WO1993014189A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU664560B2 (en) * 1991-05-23 1995-11-23 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6280962B1 (en) 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
US6322989B1 (en) 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
US6352826B1 (en) 1991-11-25 2002-03-05 Yoreh Biotechnologies, Ltd. Method and kit for the detection of retroviral specific antibodies in seronegative individuals
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
CA2188432C (fr) 1994-04-22 2011-02-01 Yutaka Kawakami Antigenes du melanome
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
PT879282E (pt) * 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
CA2272924A1 (fr) * 1996-11-22 1998-05-28 Shiloov Medical Technologies Ltd. Procede et trousse de dosage du sang entier et du facteur mitogene servant a effectuer la detection precoce du cancer chez un sujet

Also Published As

Publication number Publication date
NO942660L (no) 1994-09-16
FI943422A (fi) 1994-07-19
EP0624189A1 (fr) 1994-11-17
KR950700402A (ko) 1995-01-16
FI943422A0 (fi) 1994-07-19
AU3435293A (en) 1993-08-03
JPH07503134A (ja) 1995-04-06
WO1993014189A1 (fr) 1993-07-22
EP0624189A4 (fr) 1995-05-17
NO942660D0 (no) 1994-07-15

Similar Documents

Publication Publication Date Title
Filaci et al. CD8+ CD28− T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers
Givan et al. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens
Vedhara et al. The measurement of stress-related immune dysfunction in psychoneuroimmunology
Mathew et al. The anergic state in sarcoidosis is associated with diminished dendritic cell function
Folds et al. 24. Clinical and laboratory assessment of immunity
Becker Interferons as modulators of human monocyte-macrophage differentiation. I. Interferon-gamma increases HLA-DR expression and inhibits phagocytosis of zymosan.
Taylor et al. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms
Hou et al. Establishment of the reference intervals of lymphocyte function in healthy adults based on IFN-γ secretion assay upon phorbol-12-myristate-13-acetate/ionomycin stimulation
EP0688223A1 (fr) METHODE DE TITRAGE $i(IN VITRO) POUR LA MESURE DU DEGRE D'ACTIVATION DE CELLULES IMMUNES
CA2128424A1 (fr) Methode d'identification de precurseurs de cellules t cytolytiques
Brod et al. Lymphokine regulation of CD45R expression on human T cell clones.
Xuan et al. ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling
CN108697734A (zh) 表现出适应性表型的nk细胞以及制备和使用方法
Ghosh et al. Tumour-infiltrating lymphocytes in cervical carcinoma
US7413869B2 (en) Method for determining potency of antigenic presenting cell based vaccines
Gonzales et al. Expression and secretion levels of Th1 and Th2 cytokines in patients with aggressive periodontitis
Zhang et al. Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
KR20120004544A (ko) 항원 제시 세포에 대한 정성적 검정법
Flinn et al. Thymopoiesis, alterations in dendritic cells and Tregs, and reduced T cell activation in successful extracorporeal photopheresis treatment of GVHD
US8771971B2 (en) Methods and kits for measurement of lymphocyte function
Hritzo et al. Imaging flow cytometry: a method for examining dynamic native FOXO1 localization in human lymphocytes
Epeldegui et al. BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells
Marino et al. Differential IL-7 responses in developing human thymocytes
Ma et al. Follicular cytotoxic CD8 T cells present high cytokine expression, and are more susceptible to Breg-mediated suppression in non-small cell lung cancer
Thompson et al. Measurement of daughter cell accumulation during lymphocyte proliferation in vivo

Legal Events

Date Code Title Description
FZDE Dead